Tight transcriptional control of foreign genes introduced into the germline of transgenic mice would be of great experimental value in studies of gene function. To develop a system in which the spatial and temporal expression of candidate genes implicated in cardiac development or function could be tightly controlled in vivo, we have generated transgenic mice expressing a tetracycline-controlled transactivator (tTA) under the control of a rat alpha myosin heavy chain promoter (MHCa-tTA mice), as well as mice harboring a candidate target gene implicated in the control of differentiation, Idl (tet-Idl mice). No expression of the target transgene was detected in any tissues of hemizygous tet-Idl mice. Genetic crosses with MHCa-tTA mice resulted in transactivation of the Idl transgene, but expression was restricted to heart, where tTA was expressed. Furthermore, transactivation of the target gene was tightly and reversibly controlled by systemic therapy with tetracycline, both in utero and postnatally. These studies demonstrate the feasibility of such a binary approach for tightly controlling the timing and extent of expression of transgenes in vivo. This approach should be generally useful for the ectopic expression of candidate genes in selected tissues during delineated developmental stages. (J. Clin. Invest. 1994. 94:2421-2425 
Introduction
Molecular genetic manipulations of the mouse genome by gene addition (1) or homologous recombination (2) provide powerful approaches for evaluating gene function in vivo. Nonetheless, neither approach is well-suited for tight regulatory control of the gene of interest. Transgenes regulated by viral or mammalian control sequences often result in tissue and developmentally restricted expression, however, the extent and precise timing of expression only rarely can be experimentally manipulated. Gene disruption is by definition an all-or-none phenomenon. Thus, hypotheses that address whether the timing of a gene's induction or repression are important factors during development are currently difficult to test.
To modulate gene expression during distinct developmental windows in vivo, systems for the tightly regulated spatial and temporal control of transcription are required. Several approaches have been developed which allow for exogenous regulation of gene expression in cultured mammalian cells, including the use of heavy metal or hormonally responsive promoters (3, 4) . Other systems have relied upon modifications of bacterial genetic switches such as the lactose operon (5, 6) or the creation of unique chimeric proteins containing nonmammalian DNA binding and transcriptional activation domains to minimize expression of nontarget genes.
To gain tighter temporal control over mammalian gene expression, Gossen and Bujard (7) modified elements from the tetracycline-resistance operon in TnlO of Escherichia coli. In the bacterial system, expression of tetracycline resistance genes are repressed by binding of the tetracycline repressor (tetR) to operator (tetO) sequences located within the operon. Tetracycline inhibits tetRItetO binding and derepresses transcription. By fusing tetR with the COOH-terminal transactivation domain of herpes simplex virus VP16, a hybrid tetracycline-controlled transactivator (tTA)' was created, which induced expression of minimal promoters harboring tetO sequences. Induction was essentially completely inhibited by concentrations of tetracycline as low as 1 ug/ml in the media, which are similar to therapeutic antibiotic levels in the serum of rodents.
Recently, we demonstrated that target genes harboring tetO sequences fused to a cytomegalovirus minimal promoter could be introduced into adult rat hearts by direct intracardiac injection and that transcription of such target genes was markedly transactivated by coinjected tTA expression plasmids (8) . The level of transactivation was effectively regulated over several orders of magnitude by systemic therapy with oral tetracycline. Target gene expression could be rapidly and reversibly controlled by manipulating antibiotic treatment. However, while direct intracardiac injection of DNA with highly sensitive reporter genes is a useful technique for studies of gene transcription, the absolute number of transduced cells is limited and insufficient to influence the cardiac phenotype. Therefore, to develop an approach for the study of developmentally important genes in which both the tissue specificity and temporal profile of foreign gene expression could be highly regulated in vivo, we have examined the behavior of the tetracycline-regulated gene expression system in transgenic mice. As a model system, we have manipulated the expression of an Idl transgene in the heart. The Idl gene encodes a helix-loop-helix protein which serves as a negative regulator of differentiation in several lineages, most notably during skeletal myogenesis (9) . IdI expression is temporally and spatially regulated during cardiac development, suggesting an important role during heart formation as well (10 
Methods
Plasmid constructs. The tetracycline-controlled transactivator pa-tTA has previously been described; for simplicity, in this study it is referred to as alpha myosin heavy chain (MHCa)-tTA (8) . The tet-Idl target gene replaces the luciferase coding sequence from pUHC13-3 (7) with a SacII-EcoRI fragment from pMH18AR, which contains the mouse Idl cDNA (9) . The MHCa-tTA and tet-Idl constructs are shown schematically in Fig. 1 . All nucleic acid manipulations were carried out according to established protocols (11) . Enzymes were obtained from New England Biolabs Inc. (Beverly, MA) unless indicated otherwise.
Tetracycline treatment. A stock solution of tetracycline hydrochloride (Sigma Chemical Co., St. Louis, MO) was prepared as 100 mg/ ml in 50% ethanol and diluted to its final concentration in 2.5% sucrose in water. For some studies, the parental analogue oxytetracycline (LA200; Pfizer Inc., New York) was administered (15 mg/kg i.p.), which was prepared by dilution of a stock solution to 2 mg/ml with water.
Transgenic mouse production. The MHCa-tTA plasmid was linearized at the unique XmnI site in the vector backbone and then purified from solution using sodium iodide and silica beads (Gene Clean; Bio 101, La Jolla, CA). The tet-Idl transgene was separated from vector sequences by agarose gel electrophoresis after digestion with XhoI and BstEII and similarly purified. Transgene DNA was then equilibrated with injection buffer (10 mM Tris (pH 7.4), 0.1 mM EDTA) by spin dialysis using a filter (Microcon; Amicon Corp., Danvers, MA). Pronuclear injection was carried out in the Albert Einstein College of Medicine Transgenic Mouse Facility according to standard techniques, into a B6/ CBAFI background (12) .
Hybridization analyses. Genomic DNA was prepared from tail biopsies and 10 ,g of DNA was digested with the appropriate restriction endonuclease and size-fractionated on 1% agarose gels. After denaturation and neutralization, DNA was transferred to nylon membranes (Hybond N; Amersham International, Buckinghamshire, UK) by capillary transfer and subsequently cross-linked by ultraviolet irradiation (Stratalinker; Stratagene Inc., La Jolla, CA).
Total cellular RNA was prepared from tissue samples by the singlestep method (13). For each sample, 10 ,g of total RNA was sizefractionated on 0.8% agarose/formaldehyde gels and transferred and cross-linked as described above.
To identify tTA transgene expression, a 1-kb EcoRI-BamHI cDNA fragment from pUHD 13-3 including the tTA coding region was used. To specifically detect Idl transgene transcripts without cross-hybridization with endogenous Id sequences, a 166-bp EcoRI-HincIl cDNA fragment from the tet-Idl plasmid was used which contained sequences from the SV40 late genes included in the processed transcript. Complementary DNA probes were labeled to high specific activity by random priming using a commercial kit (Prime-It II; Stratagene Inc. To determine the effects of introduction of the MHCa-tTA transgene into the tet-Idl background, crosses between the MHCa-tTA line 25 and tet-Idl lines were carried out. Fl progeny were killed on postnatal day 1 and genotyped for each of the two transgenes, as shown in Fig. 3A Fig. 4 (A) . In doubly transgenic mice, expression of both transactivator and target genes was restricted to heart; no expression of the tet-Idl target gene was observed in brain, kidney, liver, hindlimb muscle, spleen, or tongue. Inhibition of transactivation in compound transgenic mice. We next determined whether tetracycline therapy could reversibly control the expression of the target gene and regulate tTAdependent transactivation in the hearts of compound transgenic mice. To increase the proportion of doubly transgenic offspring, the MHCa-tTA line 25 founder was mated with homozygous tet-Idl mice. To control target gene expression during cardiac development, maternally administered tetracycline must effectively cross into the fetal circulation and enter the developing heart. Therefore, we first tested the effects of maternally administered tetracycline on target gene expression in her progeny. In contrast to the results obtained in the absence of tetracycline therapy (see Fig. 3 ), no target gene transactivation was observed in the hearts of doubly transgenic offspring for the first 72 h after birth, despite abundant expression of tTA (Fig. 4 B,  lanes A-C) . Similar results were observed in eight additional compound heterozygous mice analyzed within 72 h after birth (not shown). To determine whether repression was reversible, additional doubly transgenic offspring were obtained from the same mating pair, which had again received tetracycline throughout gestation. Three doubly transgenic offspring were identified. The mother and these progeny remained off additional tetracycline therapy from the time of birth until postnatal day 10. Analysis at this time point demonstrated abundant target gene expression (lane D). Moreover, additional antibiotic therapy from postnatal days 10-13 again blocked target gene expression, to levels undetectable by Northern blot analysis (lane E). The third doubly transgenic mouse expressed negligible tTA mRNA and as expected, did not accumulate the target gene (not shown). Thus, cardiac-specific target gene expression was highly and reversibly responsive to tetracycline treatment in vivo, both prenatally, in the developing heart, as well as postnatally.
Finally, to determine whether repression of target gene transactivation in utero by maternal administration of tetracycline could be reversed more rapidly, the mating pair was supplemented with only 0.1 mg/ml tetracycline in the drinking water during gestation, which was stopped at the time of birth. Compound heterozygous offspring were identified and analyzed 24, 48, or 120 h postnatally, as shown in Fig. 4C . In contrast to the results obtained with the higher dosage of tetracycline, very weak expression of the tet-Idl target gene was observed as early as 24 h after discontinuation of antibiotic treatment 
Discussion
In these studies, we have demonstrated the functionality of the tetracycline-regulated gene expression system directly in transgenic mice. First, we have shown that transgenic mice carrying only the tTA-dependent target gene are transcriptionally silent, at least by the sensitivity of Northern blot analysis. Second, we have shown that introduction of the chimeric tTA protein by genetic means effectively transactivates the normally silent target gene. Finally, we have demonstrated that tetracycline treatment effectively represses tTA-dependent transactivation and that this effect is reversible.
The magnitude of target gene expression in the absence of expressed transactivator is a critical parameter. For some applications, even relatively minor levels of tTA-independent target gene transcription will be unacceptable. Examples of such studies might include targeted expression of toxins in fully differentiated adult cells or complex genetic complementation experiments. In our studies, we observed no detectable target gene expression, at least by the limited sensitivity of hybridization analysis. Conceivably, independent lines of mice will have varying degrees of baseline transcription, reflecting the site of chromosomal integration. such as reverse-transcription PCR, to identify lines which are truly transcriptionally inactive in the absence of tTA.
Several genetic systems already exist in which transgene expression can be modified in vivo. Binary approaches, such as the GAL4 system recently described, allow for target genes to be specifically transactivated in doubly transgenic progeny (14) . However, in this approach, the extent of transactivation is unregulated and target genes cannot be specifically repressed or activated during critical developmental stages. Altemative approaches, such as the cre-lox system of bacteriophage P1 allow for the precise recombination of foreign genetic elements in vivo, resulting in either gene activation or disruption (15). However, if cre is genetically expressed under the control of a cellular promoter, the onset of recombinase activity is limited to a single developmental stage and altematively, if the recombinase is introduced by a viral vector, the recombination event may not occur uniformly or be restricted to the tissue of interest.
In our experiments, we directed tTA expression to the heart by means of a cardiac-specific myosin heavy chain promoter. Therefore, not only could expression of the target gene be temporally and quantitatively controlled by tetracycline administration, but its spatial behavior was delineated as well. This approach enabled us to specifically transactivate the Idl transgene only within the cardiac myocyte. It should be noted that expression of tTA under the control of the short MHCa promoter showed some variability within individual litters. This may reflect background effects, or more likely, the inclusion of bacterial sequences within the injected transgene. To minimize this variability, we have now constructed transgenes in which additional 5' flanking sequences from the MHCa gene are included and all bacterial sequences have been removed. Others have reported that these modifications result in consistently high levels of cardiac-specific transgene expression in vivo (16) .
Normally, Idl expression is observed in all embryonic cell layers by 7.5 d p.c., but disappears in the heart as gastrulation ends. By 10.5 d p.c., however, Id expression is strong in the endocardial cushion region and by 13.5 d p.c., the transcript is also observed in the valves and outflow tract. By the end of gestation, Id expression within the heart is restricted to the cardiac valves (10) . Thus, the endogenous Idl gene shows a complex temporal and spatial pattem of expression suggesting an important role in cardiac development. In this study, we have not yet addressed potential phenotypic effects of IdI target gene transactivation. Given the concordance between transactivator and target gene expression in postnatal compound heterozygotes, it is likely that the tet-Idl target gene is expressed during embryogenesis, since the MHCa promoter we have used to control tTA expression is quite active during prenatal heart formation (not shown). Thus, aberrant Idl expression during the latter part of cardiac development is presumably not embryonic lethal. Conceivably, posttranscriptional mechanisms regulate the accumulation of Idl protein, mitigating the effects of target gene transactivation. Clearly, additional studies will be required to determine whether more subtle phenotypic alterations are present in these transgenic mice.
In summary, we have demonstrated the functionality of the tetracycline-regulated gene expression system in vivo after germline transfer. The ability to spatially and temporally control foreign gene expression following germline transfer should prove exceedingly useful for in vivo developmental studies.
A B tTA C tet-Idl 
